GMAB— AI Stock Forecast & Price Targets
Published 8/13/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live GMAB price forecast →
Genmab's recent EU approval of TEPKINLY and positive Phase 3 EPCORE DLBCL-4 results provide catalysts for revenue acceleration, but high debt levels and valuation sensitivity to near-term catalysts create risk. The stock is trading above the base target with strong momentum from earnings-driven optimism, though technical resistance at $31.186 may cap short-term upside.
Hold until next earnings (Nov 5) as momentum supports upside; invalidation below $29.95 would trigger trimming. Target: $31.42–$32.04 based on forecast band and recent price action.
Accumulate if the stock consolidates above $31.186, with catalysts including EU approval for TEPKINLY and Phase 3 data readouts. Expected return: 5-10% over 6 months; change of mind if debt servicing becomes unsustainable or clinical results disappoint.
Terminal thesis hinges on successful commercialization of EPKINLY/TEPKINLY in EU markets, with long-term growth driven by pipeline expansion. Structural risk is high competition in bispecific antibodies and potential regulatory delays.
Revenue growth accelerated to 25% YoY in H1 2026, driven by DARZALEX and EPKINLY sales, with non-DARZALEX products contributing half of growth. Gross margins remain robust at 93.03%, but high debt-to-equity (88.52) and low net margins (19.04%) indicate financial risk. Operating cash flow improved to $891M in Q3 2025, signaling operational maturity, though the company still faces execution risks with pipeline commercialization.
The chart shows a strong uptrend since early July, breaking above resistance at $31.186 (actual price) and aligning with the Kronos AI forecast band ($29.95-$32.04). The 50-day SMA (13.87% gain) is rising faster than the 200-day SMA, indicating momentum. However, the RSI at 71.25 suggests overbought conditions, and a break below $29.95 would invalidate the bullish trend.
Recent earnings call highlights strong revenue growth (25% YoY) and raised full-year guidance to $4.3B–$4.5B due to non-DARZALEX products. Guggenheim raised its price target to $42, but the stock is currently trading above the base target ($31.50). The market appears pricing in near-term catalysts rather than GAAP profitability, with high sensitivity to clinical data readouts.
- EU approval for TEPKINLY (follicular lymphoma) driving revenue acceleration to $4.3B–$4.5B
- Positive Phase 3 EPCORE DLBCL-4 data de-risking future pipeline revenue streams
- High debt load relative to net profitability ($5.27B total debt vs. $0.31B net income in Q2 2026)
- Execution risk with projected revenue ramp from new indications
- Intense competition within bispecific antibody space requiring continuous pipeline success
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord